431 related articles for article (PubMed ID: 30149766)
21. Advances in immunotherapy for melanoma.
Redman JM; Gibney GT; Atkins MB
BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
[TBL] [Abstract][Full Text] [Related]
22. Update on immunotherapy in melanoma.
Green J; Ariyan C
Surg Oncol Clin N Am; 2015 Apr; 24(2):337-46. PubMed ID: 25769716
[TBL] [Abstract][Full Text] [Related]
23. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
24. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
[TBL] [Abstract][Full Text] [Related]
25. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
26. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Lens M; Testori A; Ferucci PF
Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
[TBL] [Abstract][Full Text] [Related]
28. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
30. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of immunotherapy for metastatic mucosal melanoma.
Shreders A; Joseph RW
Immunotherapy; 2016 Jul; 8(8):843-5. PubMed ID: 27381682
[No Abstract] [Full Text] [Related]
32. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in advanced melanoma: a network meta-analysis.
Pyo JS; Kang G
Immunotherapy; 2017 May; 9(6):471-479. PubMed ID: 28472905
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for the management of advanced melanoma: the next steps.
Zikich D; Schachter J; Besser MJ
Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for Melanoma.
Glitza Oliva IC; Alqusairi R
Adv Exp Med Biol; 2018; 995():43-63. PubMed ID: 30539505
[TBL] [Abstract][Full Text] [Related]
37. Melanoma Immunotherapy in the Elderly.
Orloff M
Curr Oncol Rep; 2018 Mar; 20(2):20. PubMed ID: 29500787
[TBL] [Abstract][Full Text] [Related]
38. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
39. Despite past disappointments, the future of melanoma therapy appears bright.
Tarhini A
Oncology (Williston Park); 2009 May; 23(6):509, 515. PubMed ID: 19544692
[No Abstract] [Full Text] [Related]
40. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
